Related Experiment Videos
In vitro analysis of the dominant negative effect of p53 mutants
1Oncology Department, Novartis, CH-4002 Basel, Switzerland. patrick.chen@pharma.novartis.com
Abstract:
Missense mutations of the p53 tumour suppressor gene induce the formation of proteins with an altered affinity for DNA. These mutant proteins have either a wild-type or a mutant conformation. It has been established that, on association with wild-type protein, molecules with mutant conformation can drive the wild-type p53 into a mutant conformation. It is shown here that mutant proteins with a wild-type conformation can also inactivate wild-type p53 upon oligomerisation. The dominant negative activity of these mutants depends on their ability to bind to DNA. The less a mutant protein binds to DNA, the more it is dominant negative. Their dominant negative activity is also dependent on the DNA-binding site. The binding of wild-type to a low-affinity DNA element is more easily inactivated by a dominant negative mutant than its binding to a high-affinity DNA-binding site.
Insights
Missense mutations in the p53 gene create altered proteins that can inactivate normal p53. This dominant-negative effect is stronger when mutants bind DNA less effectively.
Area of Science:
- Molecular biology
- Cancer genetics
- Tumor suppressor genes
Background:
- Missense mutations in the p53 tumor suppressor gene alter protein function.
- Mutant p53 proteins can exhibit dominant-negative activity, interfering with wild-type p53 function.
Purpose of the Study:
- To investigate how p53 mutants with wild-type conformation inactivate wild-type p53.
- To determine the role of DNA binding affinity and DNA-binding sites in the dominant-negative activity of p53 mutants.
Main Methods:
- Analysis of p53 mutant protein conformation and DNA binding.
- Oligomerization studies to assess interactions between mutant and wild-type p53.
- Evaluation of p53's DNA binding to elements with varying affinities.
Main Results:
- Mutant p53 proteins with a wild-type conformation can inactivate wild-type p53 through oligomerization.
- The dominant-negative activity is inversely correlated with the mutant protein's DNA binding ability.
- Inactivation of wild-type p53 binding to low-affinity DNA sites is more pronounced than to high-affinity sites.
Conclusions:
- Both mutant and wild-type conformation p53 mutants exhibit dominant-negative effects.
- DNA binding affinity and the specific DNA-binding site are critical determinants of dominant-negative p53 activity.
- Understanding these mechanisms is crucial for p53-targeted cancer therapies.